Abstract
Bolesatine, a toxic protein isolated from Boletus satanas Lenz inhibits in vitro protein synthesis in a concentration-dependent manner in a cell line from a radiation-induced thymic lymphosarcoma (SP2/O) with a 50% inhibitory concentration (IC50) of 9.5 nM (0.6 microgram/ml). In vivo, an i.p. single injection of bolesatine, corresponding to 1/6 and 1/10 of 24-h 50% lethal dose, in Balb/c mice having ascitic tumour induced by the i.p. preinjection of SP2/O cells allows a remission of 50% and 30%, respectively. Treated mice survived 120 days after the treatment, i.e. 90 days after the death of control animals.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cell Division / drug effects
-
Cell Survival / drug effects
-
Dose-Response Relationship, Drug
-
Female
-
Fungal Proteins / administration & dosage
-
Fungal Proteins / therapeutic use
-
Fungal Proteins / toxicity*
-
Injections, Intraperitoneal
-
Kinetics
-
Lethal Dose 50
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / pathology*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Mycotoxins*
-
Neoplasms, Radiation-Induced / drug therapy
-
Neoplasms, Radiation-Induced / mortality
-
Protein Synthesis Inhibitors / therapeutic use
-
Protein Synthesis Inhibitors / toxicity*
-
Thymus Neoplasms / drug therapy
-
Thymus Neoplasms / mortality
-
Thymus Neoplasms / pathology*
-
Tumor Cells, Cultured / drug effects
Substances
-
Fungal Proteins
-
Mycotoxins
-
Protein Synthesis Inhibitors
-
Bolesatine protein, Boletus satanas